Von Hippel-Lindau disease tumor suppressor/Elongin B/Elongin C · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Protein identity stays anchored to UniProt P40337. Use UniProt P40337 as the stable identity anchor, then attach disease evidence before program review.
Use UniProt P40337 as the stable identity anchor, then attach disease evidence before program review.
von Hippel-Lindau disease tumor suppressor
Review this target as Von Hippel-Lindau disease tumor suppressor/Elongin B/Elongin C, mapped to UniProt P40337. ChEMBL maps the protein component as von Hippel-Lindau disease tumor suppressor. Sequence length is 213 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Von Hippel-Lindau disease tumor suppressor/Elongin B/Elongin C as ChEMBL target CHEMBL3301400, mapped to UniProt P40337. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Von Hippel-Lindau disease tumor suppressor/Elongin B/Elongin C is the right protein anchor across sources, using UniProt P40337 as the stable mapping.
Jump to Protein ContextUse this block first when you need the strongest disease program and evidence level in one place.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Von Hippel-Lindau disease tumor suppressor/Elongin B/Elongin C |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P40337 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | von Hippel-Lindau disease tumor suppressor |
| UniProt Accession | P40337 |
| Component Type | Protein |
| Sequence Length | 213 aa |
von Hippel-Lindau disease tumor suppressor
Review this target as Von Hippel-Lindau disease tumor suppressor/Elongin B/Elongin C, mapped to UniProt P40337. ChEMBL maps the protein component as von Hippel-Lindau disease tumor suppressor. Sequence length is 213 aa.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4244103 | 8.3 | Kd | 5.0 | Preclinical |
| CHEMBL4241500 | 8.17 | Kd | 6.7 | Preclinical |
| CHEMBL5184620 | 8.17 | IC50 | 6.8 | Preclinical |
| CHEMBL4225470 | 7.8 | Kd | 16.0 | Preclinical |
| CHEMBL5274606 | 7.62 | Kd | 24.0 | Preclinical |
| CHEMBL5421220 | 7.6 | Kd | 25.0 | Preclinical |
| CHEMBL5182441 | 7.58 | Kd | 26.0 | Preclinical |
| CHEMBL6035425 | 7.53 | Kd | 29.3 | Preclinical |
| CHEMBL5425050 | 7.47 | Kd | 34.0 | Preclinical |
| CHEMBL5592905 | 7.47 | Kd | 34.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 36 | 161 | 5.8 |
| cell-based format | 24 | 8 | 6.8 |
| assay format | 7 | 14 | 6.6 |